Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors

Deutschmann, E, Bucher, HC, Jaeckel, S, Gibbons, S, McAllister, K, Scherrer, A, Braun, D, Cavassini, M, Hachfeld, A, Calmy, A
et al (show 10 more authors) (2020) Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors. Clinical Infectious Diseases, 20 (7). p. 40.

[img] Text
SHCS_805_Manuscript_V4_Catia_AS_AH.docx - Author Accepted Manuscript

Download (419kB)


<h4>Background</h4>Prevalence of potential drug-drug interactions (PDDIs) between antiretroviral drugs (ARVs) and co-medications was high in 2008 in a Swiss HIV Cohort Study (SHCS) survey. We reassessed the prevalence of PDDIs in the era of human immunodeficiency virus (HIV) integrase inhibitors (INIs), characterized by more favorable interaction profiles.<h4>Methods</h4>The prevalence of PDDIs in treated HIV-positive individuals was assessed for the period 01-12/2018 by linkage of the Liverpool HIV drug interactions and SHCS databases. PDDIs were categorized as harmful (red flagged), of potential clinical relevance (amber flagged), or of weak clinical significance (yellow flagged).<h4>Results</h4>In 9298 included individuals, median age was 51 years (IQR, 43-58), and 72% were males. Individuals received unboosted INIs (40%), boosted ARVs (30%), and nonnucleoside reverse transcriptase inhibitor (NNRTIs) (32%)-based regimens. In the entire cohort, 68% received ≥1 co-medication, 14% had polypharmacy (≥5 co-medications) and 29% had ≥1 PDDI. Among individuals with co-medication, the prevalence of combined amber and yellow PDDIs was 43% (33% amber-mostly with cardiovascular drugs-and 20% yellow-flagged PDDIs) compared to 59% in 2008. Two percent had red-flagged PDDIs (mostly with corticosteroids), the same as in the 2008 survey. Compared with 2008, fewer individuals received boosted ARVs (-24%) and NNRTIs (-13%) but the use of co-medications was higher.<h4>Conclusions</h4>Prevalence of PDDIs was lower with more widespread use of INIs in 2018 than in 2008. Continued use of boosted regimens and increasing needs for co-medications in this aging population impeded lower rates of PDDIs.

Item Type: Article
Uncontrolled Keywords: HIV, drug-drug interactions, prevalence, Swiss HIV Cohort Study, modern antiretroviral therapy
Depositing User: Symplectic Admin
Date Deposited: 07 Oct 2020 14:11
Last Modified: 18 Jan 2023 23:29
DOI: 10.1093/cid/ciaa918
Related URLs: